Difference between revisions of "CDX2"
Jump to navigation
Jump to search
| (One intermediate revision by the same user not shown) | |||
| Line 26: | Line 26: | ||
*Intestinal adenocarcinomas. | *Intestinal adenocarcinomas. | ||
**[[Colorectal adenocarcinoma]] ~ 90% of cases.<ref name=pmid13679455/> | **[[Colorectal adenocarcinoma]] ~ 90% of cases.<ref name=pmid13679455/> | ||
*[[Neuroendocrine tumours]].<ref name=pmid15640551>{{cite journal |authors=Erickson LA, Papouchado B, Dimashkieh H, Zhang S, Nakamura N, Lloyd RV |title=Cdx2 as a marker for neuroendocrine tumors of unknown primary sites |journal=Endocr Pathol |volume=15 |issue=3 |pages=247–52 |date=2004 |pmid=15640551 |doi=10.1385/ep:15:3:247 |url=}}</ref> | |||
====Sometimes positive==== | ====Sometimes positive==== | ||
| Line 36: | Line 37: | ||
===Negative=== | ===Negative=== | ||
*[[Lung adenocarcinoma]] -ve | *[[Lung adenocarcinoma]] -ve. | ||
**<5% +ve in 20 cases.<ref name=pmid17549351>{{Cite journal | last1 = Tanaka | first1 = S. | last2 = Saito | first2 = K. | last3 = Ito | first3 = T. | last4 = Tajima | first4 = K. | last5 = Mogi | first5 = A. | last6 = Shitara | first6 = Y. | last7 = Sano | first7 = T. | last8 = Kuwano | first8 = H. | title = CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens. | journal = Oncol Rep | volume = 18 | issue = 1 | pages = 87-92 | month = Jul | year = 2007 | doi = | PMID = 17549351 }}</ref> | |||
**~12% of 93 cases +ve, all positive cases TTF-1 +ve and napsin A +ve.<ref name=pmid26469326>{{Cite journal | last1 = Cowan | first1 = ML. | last2 = Li | first2 = QK. | last3 = Illei | first3 = PB. | title = CDX-2 Expression in Primary Lung Adenocarcinoma. | journal = Appl Immunohistochem Mol Morphol | volume = 24 | issue = 1 | pages = 16-9 | month = Jan | year = 2016 | doi = 10.1097/PAI.0000000000000250 | PMID = 26469326 }}</ref> | |||
*[[Choroid plexus papilloma]]s -ve (0 in 65 cases<ref name=pmid19795349>{{Cite journal | last1 = Beschorner | first1 = R. | last2 = Mittelbronn | first2 = M. | last3 = Mugler | first3 = M. | last4 = Meyermann | first4 = R. | last5 = Schittenhelm | first5 = J. | title = Immunohistochemical analysis of CDX2 expression in normal choroid plexus epithelium and choroid plexus tumors. | journal = Histol Histopathol | volume = 24 | issue = 12 | pages = 1507-14 | month = Dec | year = 2009 | doi = | PMID = 19795349 }}</ref>). | *[[Choroid plexus papilloma]]s -ve (0 in 65 cases<ref name=pmid19795349>{{Cite journal | last1 = Beschorner | first1 = R. | last2 = Mittelbronn | first2 = M. | last3 = Mugler | first3 = M. | last4 = Meyermann | first4 = R. | last5 = Schittenhelm | first5 = J. | title = Immunohistochemical analysis of CDX2 expression in normal choroid plexus epithelium and choroid plexus tumors. | journal = Histol Histopathol | volume = 24 | issue = 12 | pages = 1507-14 | month = Dec | year = 2009 | doi = | PMID = 19795349 }}</ref>). | ||
*[[Pituitary adenoma]] & [[Craniopharyngioma]] (0 in 75 and 0 in 23 cases <ref name=pmid20602288> {{Cite journal | last1 = Schittenhelm | first1 = J. | last2 = Psaras | first2 = T. | last3 = Meyermann | first3 = R. | last4 = Honegger | first4 = J. | last5 = Beschorner | first5 = R. | title = Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms. | journal = Folia Neuropathol | volume = 48 | issue = 2 | pages = 75-80 | month = | year = 2010 | doi = | PMID = 20602288 }}</ref>). | *[[Pituitary adenoma]] & [[Craniopharyngioma]] (0 in 75 and 0 in 23 cases <ref name=pmid20602288> {{Cite journal | last1 = Schittenhelm | first1 = J. | last2 = Psaras | first2 = T. | last3 = Meyermann | first3 = R. | last4 = Honegger | first4 = J. | last5 = Beschorner | first5 = R. | title = Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms. | journal = Folia Neuropathol | volume = 48 | issue = 2 | pages = 75-80 | month = | year = 2010 | doi = | PMID = 20602288 }}</ref>). | ||
Latest revision as of 22:41, 27 January 2023
| CDX2 | |
|---|---|
| Immunostain in short | |
 CDX2 immunostaining in the papillary thyroid carcinoma cribriform morular variant. | |
| Abbreviation | CDX2 |
| Normal staining pattern | nuclear |
| Positive | colorectal adenocarcinoma, small bowel adenocarcinoma, yolk sac tumour, ovarian mucinous adenocarcinoma |
| Negative | lung adenocarcinoma |
CDX2 is a commonly used immunostain in pathology. It is a nuclear stain.
Normal
Pathology
Positive
- Intestinal adenocarcinomas.
- Colorectal adenocarcinoma ~ 90% of cases.[2]
- Neuroendocrine tumours.[3]
Sometimes positive
- Stomach adenocarcinoma ~20-30% of cases.[2]
- Esophageal adenocarcinoma ~20-30% of cases.[2]
- Ovarian mucinous adenocarcinoma[1] ~20-30% of cases.[2]
- Endometrioid endometrial adenocarcinoma ~20-30% of cases.[2]
- Yolk sac tumour (8 +ve of 20 cases[4]).
- Small bowel adenocarcinoma +ve/-ve (~43% +ve in series of 189 cases[5]).
Negative
- Lung adenocarcinoma -ve.
- Choroid plexus papillomas -ve (0 in 65 cases[8]).
- Pituitary adenoma & Craniopharyngioma (0 in 75 and 0 in 23 cases [9]).
References
- ↑ 1.0 1.1 Groisman, GM.; Meir, A.; Sabo, E. (Jan 2004). "The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.". Int J Gynecol Pathol 23 (1): 52-7. doi:10.1097/01.pgp.0000101141.31270.a0. PMID 14668551.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Moskaluk, CA.; Zhang, H.; Powell, SM.; Cerilli, LA.; Hampton, GM.; Frierson, HF. (Sep 2003). "Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays.". Mod Pathol 16 (9): 913-9. doi:10.1097/01.MP.0000086073.92773.55. PMID 13679455.
- ↑ Erickson LA, Papouchado B, Dimashkieh H, Zhang S, Nakamura N, Lloyd RV (2004). "Cdx2 as a marker for neuroendocrine tumors of unknown primary sites". Endocr Pathol 15 (3): 247–52. doi:10.1385/ep:15:3:247. PMID 15640551.
- ↑ Bing, Z.; Pasha, T.; Tomaszewski, JE.; Zhang, P. (Oct 2009). "CDX2 expression in yolk sac component of testicular germ cell tumors.". Int J Surg Pathol 17 (5): 373-7. doi:10.1177/1066896909338598. PMID 19578052.
- ↑ Jun, SY.; Eom, DW.; Park, H.; Bae, YK.; Jang, KT.; Yu, E.; Hong, SM. (Mar 2014). "Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma.". Mod Pathol. doi:10.1038/modpathol.2014.36. PMID 24603585.
- ↑ Tanaka, S.; Saito, K.; Ito, T.; Tajima, K.; Mogi, A.; Shitara, Y.; Sano, T.; Kuwano, H. (Jul 2007). "CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens.". Oncol Rep 18 (1): 87-92. PMID 17549351.
- ↑ Cowan, ML.; Li, QK.; Illei, PB. (Jan 2016). "CDX-2 Expression in Primary Lung Adenocarcinoma.". Appl Immunohistochem Mol Morphol 24 (1): 16-9. doi:10.1097/PAI.0000000000000250. PMID 26469326.
- ↑ Beschorner, R.; Mittelbronn, M.; Mugler, M.; Meyermann, R.; Schittenhelm, J. (Dec 2009). "Immunohistochemical analysis of CDX2 expression in normal choroid plexus epithelium and choroid plexus tumors.". Histol Histopathol 24 (12): 1507-14. PMID 19795349.
- ↑ Schittenhelm, J.; Psaras, T.; Meyermann, R.; Honegger, J.; Beschorner, R. (2010). "Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms.". Folia Neuropathol 48 (2): 75-80. PMID 20602288.